Ads
related to: cervical cancer, approved- Advanced Cervical Cancer
Read About a Treatment Option
And The Benefits And Risks
- Clinical Study Trials
Clinical Study Results Information
Learn More Here Today
- Hear From a Patient
See How Patients Get The Chance
To Tell Their Story
- Access & Reimbursement
Do You Need Help To
Access Your Treatment?
- Advanced Cervical Cancer
Search results
HPV vaccine provides real benefits for men, analysis shows
Reuters· 6 days agoVaccination of boys and men against the human papillomavirus (HPV) reduces their risk of head and...
HPV vaccine provides real benefits for men, analysis shows
KSL Salt Lake City· 4 days agoVaccination of boys and men against the human papillomavirus reduces their risk of head and neck ...
Blood test to detect colon cancer could move a step closer to FDA approval in the US
WPBF West Palm Beach· 7 days agoTo screen for colon and rectal cancers, most people have colonoscopies, which can feel invasive and...
Antengene To Present One Oral and Four Abstracts at ASCO 2024
WPRI Providence· 6 days ago...Meeting, taking place from May 31st to June 4th at the McCormick Place Convention Center in Chicago, IL, the United States. 31 checkpoint inhibitor (CPI)-naïve cervical cancer patients who previously had at least one systemic line of chemotherapy were enrolled in the TORCH-2 study as of Oct 20th...
Regeneron (REGN) Announces Positive Data on Oncology Candidate
Zacks via Yahoo Finance· 6 days agoRegeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 6 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results from an ongoing Phase 1/2 trial evaluating its first-in-class costimulatory bispecific antibody, REGN7075 ...
Anti-Cancer Drug Pembrolizumab: Frequently Used Alone Or With Other Treatments
Forbes· 3 days agoPembrolizumab, sold as Keytruda by Merck & Co., was one of the first inhibitors to hit the market. A...
Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual...
FOX 59 Indianapolis· 6 days agoMabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 6 days agoIovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer ...
Regeneron (REGN) Announces Positive Data on Oncology Candidate
Zacks· 6 days agoFree Report) announced positive new results from an ongoing phase I/II study on pipeline candidate REGN7075. The phase I/II first-in-human, open-label study is evaluating REGN7075, in combination ...